Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

3rd international symposium on genetic anticancer agents.

Piotr J Wysocki1, Malgorzata Mackiewicz-Wysocka

  • 1Department of Cancer Immunology, Chair of Oncology, USOMS, at GreatPoland Cancer Center, Garbary Street 15, 61-866 Poznan, Poland. pwysocki@plusnet.pl

Expert Opinion on Biological Therapy
|June 25, 2002
PubMed
Summary

The 3rd International Symposium on Genetic Anticancer Agents highlighted novel genetic strategies for cancer treatment. Experts discussed preclinical and clinical advancements in gene therapy and trial design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pretreatment NPLH as a Potential Predictor of Pathologic Complete Response to Accelerated MVAC Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Comparison with NLR and PLR.

Cancers·2026
Same author

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Nature cancer·2026
Same author

Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Post-Chemotherapy Antibody-Based Continuation and Maintenance Strategies in HER2-Positive Metastatic Breast Cancer: A Translational Narrative Review.

Antibodies (Basel, Switzerland)·2026
Same author

The phase III MECCA study on metronomic chemo-endocrine therapy in advanced breast cancer-the results that so many have been waiting for.

Chinese clinical oncology·2026
Same author

Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review.

Oncology and therapy·2025

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • The NDDO Research Foundation convened the 3rd International Symposium on Genetic Anticancer Agents.
  • The symposium focused on the development of novel genetic agents for cancer therapy.

Framework:

  • The event featured presentations by leading global experts in cancer research.
  • Discussions centered on preclinical and clinical advancements in genetic anticancer agents.

Implementation:

  • Scientific sessions showcased recent research findings and novel treatment approaches.
  • An educational session addressed the gene therapy product development process and clinical trial design.

Implications:

  • The symposium facilitated knowledge exchange on cutting-edge genetic anticancer strategies.

Related Experiment Videos

  • It underscored the importance of interdisciplinary collaboration in advancing cancer treatment.